LICITRA, LISA FRANCESCA LINDA
LICITRA, LISA FRANCESCA LINDA
Dipartimento di Oncologia ed Emato-Oncologia
INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2026 D. Rischin, A. R Hansen, E.E. W Cohen, M. Tahara, K. J Harrington, R. I Haddad, L. Licitra, H. Mehanna, R. L Ferris, P. Koralewski
Risk of employment separation among workers with head and neck cancer: a longitudinal cohort study in Turin
2026 E. Farina, L. Licitra, F. Mercalli, S. Massari, A. Marinaccio, C. Gariazzo, L. Taiano, R. Foggetti, N. Zengarini, A. Trama, S. Cavalieri, A. Manocchio, E. Martinelli, F. Mazzetti, C. Vener, G. Pravettoni, D. Monzani, G. Marton, M. Vitali, I. Nuzzolese, E. Colombo, A. Ottini, C. Resteghini, C. Airoldi, L. López Pérez, G. Fico, M.F. Cabrera, S. Singer, K.J. Taylor
Mutational Landscape of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Association with Immune Checkpoint Inhibitor Outcomes
2025 P. Mccoon, Y. Wang, Z. Lai, Q. Zhang, W. Li, S. Wildsmith, N. Morsli, R. Raja, N. Holoweckyj, J. Walker, M. De Los Reyes, R. Mesia, L. Licitra, R.L. Ferris, J. Fayette, D.P. Zandberg, L.L. Siu, R. Haddad
INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2025 J. Fayette, L. Licitra, K. Harrington, R. Haddad, L.L. Siu, Y.-. Liu, M. Tahara, J.-. Machiels, D. Rischin, T.Y. Seiwert, R.L. Ferris, U. Keilholz, A. Psyrri, B. Keam, P. Bossi, R. Metcalf, C.-. Hsieh, P.M.J. Clement, P. Isaev, A. Mudunov, J. Dinis, A. Hoeben, S. Kasper, K. Klinghammer, M. Hwang, J. Blando, O. Serrano, D. Ruscica, R.B. Cohen
International consensus on laryngeal preservation strategies in laryngeal and hypopharyngeal canonccer
2025 M. Ferrari, F. Mularoni, D. Smussi, P. Gaudioso, P. Bonomo, J. Friborg, M.G. Ghi, V. Gregoire, K. Harrington, K. Hunter, R. Maroldi, R. Martino, R. Mesia, G. Peretti, A. Psyrri, A. Schindler, G. Succo, P. Szturz, I. Vilaseca, P. Nicolai, P. Bossi, J.P. Agarwal, M. Ansarin, A. Argiris, P. Balermpas, N.M.L. Battisti, E. Bellini, A. Bertolin, A.L.C. Carobbio, C.M. Chiesa-Estomba, B. Cirauqui, E. Crosetti, T.B. De Oliveira, A. Deganello, A. Dietz, J.G. Eriksen, A. Eskander, N. Fakhry, A. Falco, D. Farina, R. Ferrarotto, C. Franzese, S. Ghosh Laskar, W. Golusinski, E.Y. Hanna, J.C. Irish, N. Kiyota, L.P. Kowalski, S. Krishnan, N. Lee, C.R. Leemans, L. Licitra, L.D. Locati, J.-. Machiels, F. Marchi, D. Mattavelli, H. Mehanna, G. Mercante, N. Montalto, P. Morbini, B. O'Sullivan, M. Oliva, E. Orlandi, A. Paderno, V. Paleri, F. Pameijer, F. Perri, R. Persio, C. Piazza, Y. Pointreau, L. Presutti, M. Ravanelli, D. Rischin, J.P. Rodrigo, A. Ruaro, G. Sanguineti, C. Simon, L. Siu, A. Spreafico, G. Spriano, S. Taboni, U. Tassini, S. Tribius, M. Van Den Brekel, V. Vander Poorten, D. Viros Porcuna
STELLAR-305: phase II/III study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with HNSCC
2025 N.F. Saba, K. Harrington, L. Licitra, J.-. Machiels, C. He, T. Jew, V. Andrianov, R. Haddad
Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study
2025 J. Bourhis, L. Licitra, B. Burtness, A. Psyrri, R. Haddad, K. Harrington, E.E.W. Cohen, J.D. Schoenfeld
Prognostic gene expression signatures for HPV-negative head and neck squamous cell carcinoma
2025 S. Cavalieri, R.H. Brakenhoff, C.R. Leemans, F.J.P. Hoebers, T. Poli, K. Scheckenbach, N.A. Iacovelli, M. Franceschini, E. Orlandi, L. Licitra, L. De Cecco
Multimodality immunotherapy with avelumab, short-course radiotherapy, and cyclophosphamide in head and neck cancer: the CONFRONT phase I-II trial
2025 M.C. Merlano, N. Denaro, M. Paccagnella, A. Abbona, D. Galizia, S. Alfieri, C. Bergamini, E. Orlandi, A.M. Merlotti, S. Bondi, L. Licitra, O. Garrone
Interplay between MRI radiomics and immune gene expression signatures in oral squamous cell carcinoma
2025 A. Corti, D. Lenoci, V.D.A. Corino, D. Mattavelli, M. Ravanelli, T. Poli, S. Cavalieri, L. Licitra, L. De Cecco, L. Mainardi
Ferroptosis-Related Gene Signatures: Prognostic Role in HPV-Positive Oropharyngeal Squamous Cell Carcinoma
2025 D. Lenoci, M.S. Serafini, M. Lucchetta, S. Cavalieri, R.H. Brakenhoff, F. Hoebers, K. Scheckenbach, T. Poli, L. Licitra, L. De Cecco
Transcriptomic based prognostic model versus TNM 9th edition in HPV-positive oropharyngeal cancer
2025 S. Cavalieri, R.H. Brakenhoff, C.R. Leemans, F. Hoebers, K. Scheckenbach, T.K. Hoffmann, D. Mattavelli, T. Poli, E. Orlandi, L. Licitra, L. De Cecco
Personalized treatment in HPV+ oropharynx cancer using genomic adjusted radiation dose
2025 E. Ho, L. De Cecco, S.A. Eschrich, S. Cavalieri, G. Sedor, F. Hoebers, R.H. Brakenhoff, K. Scheckenbach, T. Poli, K. Yang, J.A. Scarborough, S. Nellore, S. Campbell, N. Woody, T. Chan, J. Miller, N. Silver, S. Koyfman, J. Bates, J.J. Caudell, M.W. Kattan, L. Licitra, J.F. Torres-Roca, J.G. Scott
Lenvatinib in advanced thyroid, salivary gland, endometrial, and hepatocellular carcinomas: a real-world study on treatment duration and toxicity management
2025 E. Colombo, M. Ducceschi, S. Cavalieri, M. Polignano, M. Bini, P. Ambrosini, M. De Monte, G. Montelatici, A. Russo, V. Bellia, S. Bhoori, C. Bergamini, S. Alfieri, I. Nuzzolese, A. Ottini, V. Mazzaferro, F. Raspagliesi, L. Licitra, M. Mantiero
Immunotherapy followed by cetuximab in locally advanced/metastatic cutaneous squamous cell carcinomas: the I-TACKLE trial
2025 P. Bossi, A. Alberti, C. Bergamini, C. Resteghini, L.D. Locati, S. Alfieri, S. Cavalieri, E. Colombo, C. Gurizzan, L. Lorini, V. Tovazzi, M. Zamparini, M. Ravanelli, P.A. Ascierto, V. Rampinelli, A. Grammatica, R. Patuzzo, A. Maurichi, L.F. Licitra
Buparlisib and Paclitaxel in Patients with Head and Neck Squamous Cell Carcinoma: Immunogenomic Biomarkers of Efficacy from the BERIL-1 Study
2025 A. Desilets, J. Lucas, L.F. Licitra, S. Lu, A. Tse, T. Tang, K. Dreyer, N. He, L.E. Birgerson, S. Faivre, D. Soulières
A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)
2025 R. Galot, C. Le Tourneau, L. Licitra, J. Guigay, A. Kong, I. Tinhofer, C. Even, A. Daste, S. Henry, C. Borel, C. Abdeddaim, E. Seront, J.B. Prevost, A. Rutten, E. Saada-Bouzid, F. Rolland, P. Bonomo, M. Rasschaert, L. Dirix, C. Olungu, K. Tsechilidou, A.S. Govaerts, C. Fortpied, A. Joaquim, J.P. Machiels
The role of volumetry in sinonasal cancer response assessment to induction chemotherapy, results from two phase II non-randomized controlled prospective multicentric trials: SINTART-1 and SINTART-2
2025 P. Rondi, D. Mattavelli, V. Rampinelli, A. Schreiber, E. Orlandi, B. Vischioni, N.A. Iacovelli, G. Calareso, C. Bergamini, S. Alfieri, P. Castelnuovo, P. Battaglia, M. Turri-Zanoni, P. Nicolai, M. Ferrari, L. Licitra, P. Bossi, D. Farina, M. Ravanelli, C. Resteghini
Treatment-related mortality in head and neck cancer patients receiving chemotherapy and radiation: results of a meta-analysis of published trials
2025 C. Gurizzan, M. Cinquini, L. Legramandi, C. Resteghini, M. Siano, C. Bergamini, L. Lorini, D. Smussi, A. Paderno, L. Licitra, P. Bossi
The chemo-free approach for PDL1-positive platinum-sensitive recurrent/metastatic head and neck squamous cell carcinoma: Viable option or misguided myth?
2025 S. Cavalieri, N. Crippa, B. Lombardi Stocchetti, L. Licitra